{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T09:30:24Z","timestamp":1785403824228,"version":"3.56.0"},"reference-count":36,"publisher":"Impact Journals, LLC","issue":"30","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Oncotarget"],"published-print":{"date-parts":[[2015,10,6]]},"DOI":"10.18632\/oncotarget.5092","type":"journal-article","created":{"date-parts":[[2015,9,29]],"date-time":"2015-09-29T21:54:23Z","timestamp":1443563663000},"page":"29889-29900","source":"Crossref","is-referenced-by-count":58,"title":["Pretreatment with VEGF(R)-inhibitors reduces interstitial fluid pressure, increases intraperitoneal chemotherapy drug penetration, and impedes tumor growth in a mouse colorectal carcinomatosis model"],"prefix":"10.18632","volume":"6","author":[{"given":"F\u00e9lix","family":"Gremonprez","sequence":"first","affiliation":[{"name":"Department of Surgery, Ghent University Hospital, Ghent, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benedicte","family":"Descamps","sequence":"additional","affiliation":[{"name":"Infinity (iMinds-IBiTech-MEDISIP), Department of Electronics and Information Systems, Ghent University, Ghent, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrei","family":"Izmer","sequence":"additional","affiliation":[{"name":"Atomic and Mass Spectrometry, Department of Analytical Chemistry, Ghent University, Ghent, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Vanhove","sequence":"additional","affiliation":[{"name":"Infinity (iMinds-IBiTech-MEDISIP), Department of Electronics and Information Systems, Ghent University, Ghent, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank","family":"Vanhaecke","sequence":"additional","affiliation":[{"name":"Atomic and Mass Spectrometry, Department of Analytical Chemistry, Ghent University, Ghent, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivier","family":"De Wever","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology and Experimental Cancer Research, Ghent University, Ghent, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wim","family":"Ceelen","sequence":"additional","affiliation":[{"name":"Department of Surgery, Ghent University Hospital, Ghent, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"7892","published-online":{"date-parts":[[2015,9,7]]},"reference":[{"key":"1","article-title":"Cytoreduction and HIPEC in The Netherlands: Nationwide Long-term Outcome Following the Dutch Protocol","author":"Verwaal","year":"2013","journal-title":"Annals of surgical oncology"},{"key":"2","doi-asserted-by":"crossref","first-page":"3737","DOI":"10.1200\/JCO.2003.04.187","article-title":"Randomized trial of cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy and palliative surgery in patients with peritoneal carcinomatosis of colorectal cancer","volume":"21","author":"Zoetmulder","year":"2003","journal-title":"Journal of clinical oncology : official journal of the American Society of Clinical Oncology"},{"key":"3","doi-asserted-by":"crossref","first-page":"2426","DOI":"10.1245\/s10434-008-9966-2","article-title":"8-year follow-up of randomized trial: cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy in patients with peritoneal carcinomatosis of colorectal cancer","volume":"15","author":"van Tinteren","year":"2008","journal-title":"Annals of surgical oncology"},{"key":"4","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1038\/nrclinonc.2009.217","article-title":"Intraperitoneal therapy for peritoneal tumors: biophysics and clinical evidence","volume":"7","author":"Flessner","year":"2010","journal-title":"Nature reviews Clinical oncology"},{"key":"5","doi-asserted-by":"crossref","first-page":"203","DOI":"10.2165\/11598890-000000000-00000","article-title":"Pharmacokinetics and pharmacodynamics of intraperitoneal cancer chemotherapeutics","volume":"51","author":"Clarke","year":"2012","journal-title":"Clinical pharmacokinetics"},{"key":"6","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1038\/nrc1456","article-title":"High interstitial fluid pressure - an obstacle in cancer therapy","volume":"4","author":"Ostman","year":"2004","journal-title":"Nature reviews Cancer"},{"key":"7","doi-asserted-by":"crossref","first-page":"2729","DOI":"10.1158\/0008-5472.CAN-06-4102","article-title":"Effect of vascular normalization by antiangiogenic therapy on interstitial hypertension, peritumor edema, and lymphatic metastasis: insights from a mathematical model","volume":"67","author":"Munn","year":"2007","journal-title":"Cancer research"},{"key":"8","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.ijpharm.2014.12.025","article-title":"Stability of oxaliplatin in chloride-containing carrier solutions used in hyperthermic intraperitoneal chemotherapy","volume":"479","author":"Verwaal","year":"2015","journal-title":"International journal of pharmaceutics"},{"key":"9","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1023\/B:PHAM.0000026444.67883.83","article-title":"Oxaliplatin degradation in the presence of chloride: identification and cytotoxicity of the monochloro monooxalato complex","volume":"21","author":"Ehrsson","year":"2004","journal-title":"Pharmaceutical research"},{"key":"10","doi-asserted-by":"crossref","first-page":"3020","DOI":"10.1200\/JCO.2008.21.1771","article-title":"Efficacy, safety, and biomarkers of neoadjuvant bevacizumab, radiation therapy, and fluorouracil in rectal cancer: a multidisciplinary phase II study","volume":"27","author":"Vujaskovic","year":"2009","journal-title":"Journal of clinical oncology : official journal of the American Society of Clinical Oncology"},{"key":"11","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1007\/978-1-4613-1247-5_23","article-title":"Clinical research methodologies in diagnosis and staging of patients with peritoneal carcinomatosis","volume":"82","author":"Sugarbaker","year":"1996","journal-title":"Cancer treatment and research"},{"key":"12","first-page":"2929","article-title":"Inhibition of platelet-derived growth factor receptors reduces interstitial hypertension and increases transcapillary transport in tumors","volume":"61","author":"Rubin","year":"2001","journal-title":"Cancer research"},{"key":"13","doi-asserted-by":"crossref","first-page":"2277","DOI":"10.1016\/j.biomaterials.2012.12.012","article-title":"The reduction of tumor interstitial fluid pressure by liposomal imatinib and its effect on combination therapy with liposomal doxorubicin","volume":"34","author":"Zhang","year":"2013","journal-title":"Biomaterials"},{"key":"14","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.mvr.2007.05.003","article-title":"Tumor microvasculature and microenvironment: targets for anti-angiogenesis and normalization","volume":"74","author":"Jain","year":"2007","journal-title":"Microvascular research"},{"key":"15","article-title":"Intraperitoneal chemotherapy (IPC) for peritoneal carcinomatosis: Review of animal models","author":"Ceelen","year":"2013","journal-title":"Journal of surgical oncology"},{"key":"16","doi-asserted-by":"crossref","first-page":"2205","DOI":"10.1200\/JCO.2012.46.3653","article-title":"Normalizing tumor microenvironment to treat cancer: bench to bedside to biomarkers","volume":"31","author":"Jain","year":"2013","journal-title":"Journal of clinical oncology : official journal of the American Society of Clinical Oncology"},{"key":"17","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1038\/nm988","article-title":"Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer","volume":"10","author":"Clark","year":"2004","journal-title":"Nature medicine"},{"key":"18","doi-asserted-by":"crossref","first-page":"442","DOI":"10.3390\/pharmaceutics4030442","article-title":"Practical dynamic contrast enhanced MRI in small animal models of cancer: data acquisition, data analysis, and interpretation","volume":"4","author":"Yankeelov","year":"2012","journal-title":"Pharmaceutics"},{"key":"19","doi-asserted-by":"crossref","first-page":"1798","DOI":"10.1158\/1535-7163.MCT-09-0856","article-title":"Effect of pazopanib on tumor microenvironment and liposome delivery","volume":"9","author":"Dewhirst","year":"2010","journal-title":"Molecular cancer therapeutics"},{"key":"20","doi-asserted-by":"crossref","first-page":"2816","DOI":"10.1158\/0008-5472.CAN-13-2986","article-title":"Transient antiangiogenic treatment improves delivery of cytotoxic compounds and therapeutic outcome in lung cancer","volume":"74","author":"Ullrich","year":"2014","journal-title":"Cancer research"},{"key":"21","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1186\/1476-4598-9-276","article-title":"Butyrate suppresses expression of neuropilin I in colorectal cell lines through inhibition of Sp1 transactivation","volume":"9","author":"Corfe","year":"2010","journal-title":"Molecular cancer"},{"key":"22","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1016\/j.ccell.2014.10.006","article-title":"Antiangiogenesis strategies revisited: from starving tumors to alleviating hypoxia","volume":"26","author":"Jain","year":"2014","journal-title":"Cancer cell"},{"key":"23","doi-asserted-by":"crossref","first-page":"3528","DOI":"10.1158\/1078-0432.CCR-0957-03","article-title":"Imatinib mesylate efficiently achieves therapeutic intratumor concentrationsbut has limited activity in a xenograft model of small cell lung cancer","volume":"10","author":"Ilaria","year":"2004","journal-title":"Clinical cancer research : an official journal of the American Association for Cancer Research"},{"key":"24","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1186\/1478-811X-11-97","article-title":"Targeting the PDGF signaling pathway in tumor treatment","volume":"11","author":"Heldin","year":"2013","journal-title":"Cell Communication and Signaling"},{"key":"25","doi-asserted-by":"crossref","first-page":"1874","DOI":"10.1002\/bjs.7249","article-title":"Intraoperative hyperthermic intraperitoneal chemotherapy after cytoreductive surgery for peritoneal carcinomatosis in an experimental model","volume":"97","author":"de Hingh","year":"2010","journal-title":"The British journal of surgery"},{"key":"26","doi-asserted-by":"crossref","first-page":"4218","DOI":"10.1245\/s10434-014-3869-1","article-title":"Predictive and prognostic survival factors in peritoneal carcinomatosis from appendiceal cancer after cytoreductive surgery with hyperthermic intraperitoneal chemotherapy","volume":"21","author":"Gushchin","year":"2014","journal-title":"Annals of surgical oncology"},{"key":"27","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1200\/JCO.2006.09.6305","article-title":"Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200","volume":"25","author":"Benson","year":"2007","journal-title":"Journal of clinical oncology : official journal of the American Society of Clinical Oncology"},{"key":"28","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1136\/gutjnl-2011-301585","article-title":"Metronomic oral topotecan prolongs survival and reduces liver metastasis in improved preclinical orthotopic and adjuvant therapy colon cancer models","volume":"62","author":"Kerbel","year":"2013","journal-title":"Gut"},{"key":"29","doi-asserted-by":"crossref","first-page":"1566","DOI":"10.1038\/bjc.2013.140","article-title":"Neoadjuvant FOLFIRI+bevacizumab in patients with resectable liver metastases from colorectal cancer: a phase 2 trial","volume":"108","author":"Iaffaioli","year":"2013","journal-title":"British journal of cancer"},{"key":"30","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1097\/SLA.0b013e3181deb67f","article-title":"Liver resection remains a safe procedure after neoadjuvant chemotherapy including bevacizumab: a case-controlled study","volume":"252","author":"Gruenberger","year":"2010","journal-title":"Annals of surgery"},{"key":"31","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1038\/bjc.2012.342","article-title":"Neoadjuvant bevacizumab persistently inactivates VEGF at the time of surgery despite preoperative cessation","volume":"107","author":"Brostjan","year":"2012","journal-title":"British journal of cancer"},{"key":"32","doi-asserted-by":"crossref","first-page":"e47","DOI":"10.1093\/nar\/gkl051","article-title":"Adduct-specific monoclonal antibodies for the measurement of cisplatin-induced DNA lesions in individual cell nuclei","volume":"34","author":"Thomale","year":"2006","journal-title":"Nucleic acids research"},{"key":"33","doi-asserted-by":"crossref","first-page":"2398","DOI":"10.1007\/s11095-012-0765-x","article-title":"Development of a nanocrystalline Paclitaxel formulation for HIPEC treatment","volume":"29","author":"Vervaet","year":"2012","journal-title":"Pharmaceutical research"},{"key":"34","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1016\/j.mvr.2008.08.002","article-title":"Measuring interstitial fluid pressure with fiberoptic pressure transducers","volume":"77","author":"Ozerdem","year":"2009","journal-title":"Microvascular research"},{"key":"35","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1016\/j.ijrobp.2005.10.026","article-title":"Noninvasive monitoring of radiotherapy-induced microvascular changes using dynamic contrast enhanced magnetic resonance imaging (DCE-MRI) in a colorectal tumor model","volume":"64","author":"Pattyn","year":"2006","journal-title":"International journal of radiation oncology, biology, physics"},{"key":"36","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1038\/nmeth.2019","article-title":"Fiji: an open-source platform for biological-image analysis","volume":"9","author":"Cardona","year":"2012","journal-title":"Nat Meth"}],"container-title":["Oncotarget"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.oncotarget.com\/lookup\/doi\/10.18632\/oncotarget.5092","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,13]],"date-time":"2020-05-13T17:02:47Z","timestamp":1589389367000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.oncotarget.com\/lookup\/doi\/10.18632\/oncotarget.5092"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,9,7]]},"references-count":36,"journal-issue":{"issue":"30","published-print":{"date-parts":[[2015,10,6]]}},"alternative-id":["5092","26375674"],"URL":"https:\/\/doi.org\/10.18632\/oncotarget.5092","relation":{},"ISSN":["1949-2553"],"issn-type":[{"value":"1949-2553","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,9,7]]}}}